CAPOX Regimen — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	36	22	19	63	—	—	2002-08
Malignant Rectal Neoplasm	Phase3	Phase 3	14	5	8	23	—	—	2010-01
Malignant Colon Neoplasm	Phase3	Phase 3	3	2	1	6	—	—	Jun 16, 2020
Malignant Gastric Neoplasm	Phase3	Phase 3	3	3	2	7	—	—	2014-02
Malignant Pancreatic Neoplasm	Phase2	Phase 2	1	1	0	1	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CLDN18 positive1
CAPOX Regimen + Zolbetuximab

Clinical trials

Trials with this intervention (66)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 66 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07700979	Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma(G/GEJ)	recruiting	Phase 3	900	AkesoINDUSTRY	4	Sep 29, 2026	clinicaltrials
NCT05482893	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)